| Abatacept | Orencia® | Psoriatic arthritis after DMARDs NICE TA568
appraisal terminated.
NOT recommended for prescribing on the NHS in Lancashire
| Formulary BNF 10.1.3 |
| ActiPatch® | ActiPatch® | Chronic pain (presence of pain lonfer than 3 months) associated with knee osteoarthritis and plantar fasciitis | Forumlary BNF 4.7 |
| Actos® | Actos® | Generic prescribing only | Formulary BNF 6.1
|
| ACWY vaccine | | Travel vaccination | See Position Statement |
| Afatininb | | Locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy Appraisal Terminated | Formulary BNF 8.1 |
| Aflibercept | Zaltrap® | Metastatic colorectal cancer
NICE TAG307
| Formulary BNF 8.1
|
| Agomelatine | Valdoxan® | Major depression | Formulary BNF 4.3
|
| Alectinib | Alecensa® | Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) NICE TA438 | Formulary BNF 8.1 |
| Alendronate and Vitamin D | Fosavance® | Postmenopausal osteoporosis | Formulary BNF 6.6
|
| Alimemazine tablets and liquid | All brands | antihistamine | Formulary BNF 3.4 |
| Aliskiren | | Non-formulary in line with NHSE low priority prescribing commissioning agenda | Formulary BNF 2>5 |
| Alpelsib | Piqray | NICE is unable to make a recommendation alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer NICE TA652 | Formulary BNF 8>1 |
| Amantadine | Lysovir® | Influenza treatment & prophylaxis
NICE TA158, TA168 | Formulary BNF 5.3
|
Amifampridine
| Firdapse® | Lambert-Eaton Syndrome
| Formulary BNF 10.2
|
| Amoxycillin (nebulised) | | Not licensed for use via nebulised route for bronchiectasis or any other indication | Formulary BNF 5.1
|
| Anakinra | Kineret® | Rheumatoid arthritis - NICE TA72
| Formulary BNF 10.3
|
| Anti-thymocyte globulin (Riabbit) | Thymoblobuline® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Apremilast | Otezla | Moderate to severe plaque psoriasis. NICE TA368
| Formulary BNF 10.1
|
Aprovel®
| Aprovel® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Aricept® | Aricept® | Generic Prescribing Only
| Formulary BNF 4.11
|
| Armour Thyroid | Armour Thyroid | Hypothyroidism.
UKMI Q&A Statement
Statement from British Thyroid Association
| Formulary BNF 6.2
|
| Asenapine | Sycrest® | Schizophrenia/bipolar mania
| Formulary BNF 4.2
|
| Atezolizumab | Tecentriq® | Untreated advanced non-squamous non-small-cell lung cancer - Not recommended as in NICE TA618 | Formulary BNF 8.1 |
| Atorvastatin chewable tablets | Lipitor chewable® | Hypercholesterolaemia
| Formulary BNF 2.12
|
| Azacitidine | Vidaza® | Acute myeloid leukaemia
NICE TAG399
| Formulary BNF 8.1
|
| Azelastine/ Fluticase | Dymista® | Moderate to severe allergic rhinitis
| Formulary BNF 12.2
|
| Azilsartan | Edarbi® | Hypertension
| Formulary BNF 2.5
|
| Bazedoxefine | Duavive® | Oestrogen deficiency symptoms.
| Formulary BNF 6.4
|
| BCG vaccine | | Travel vaccination | See Position Statement |
| Belatacept | Nulojix® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Bendamustine | Levact® | Non-Hodgkins lymphoma. NICE TA206
Appraisal terminated. | Formulary BNF 8.1
|
| Betamethasone valerate Medicated Plasters | Betesil® | Severe eczema; psoriasis | Formulary BNF 13.4
|
| Bevacizumab | Avastin® | NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche.
NICE TA560 | Formulary BNF 8.1 |
| Bevacizumab | Avastin® | Relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
NICE TA353 Appraisal terminated.
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Monotherapy or combination chemotherapy of metastatic colorectal cancer, 2nd line NICE TA242 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Lung cancer, NSC NICE TA148
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Renal cell carcinoma NICE TA178
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with a taxane for metastatic breast cancer, 1st line NICE TA214 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | Diabetic Macular Oedema
| Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with paclitaxel and carboplatin for 1st line treatment of advanced ovarian carcinoma NICE TA284 | Formulary BNF 8.1
|
| Bevacizumab | Avastin® | In combination with gemcitabine and carboplatin for treating 1st recurrence of platinum-sensitive advanced ovarian carcinoma
NICE TA285 | Formulary BNF 8.1
|
| Bevacizumab | Avastin®
| EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) NICE TA436
| Formulary BNF 8.1 |
| Bezlotuxumab | Zinplava® | Preventing current clostridium difficile infection -appraisal terminated -NICE TA601 | Formulary BNF |
| Biatain-IBU® | Biatain-IBU® | Polyurethane foam film dressing | Wound Care Formulary
|
| Blinatumomab | Blincyto | Previously treated Pghiladelphia-chromosome- positive acute lymphoblastic leukaemia - NICE TA686 [Appraisal terminated] | Formulary 8.2.3 |
| Bortezomib | Velcade® | Multiple myeloma after second or subsequent relapse. terminate appraisal | Formulary 8.1.5 |
| Bosutinib | Bosulif | Untreated chronic myeloid leukamia in adults _ NICE TA576 - appraisal terminated
NOT recommended for prescribing on the NHS in Lancashire
| Formulary 8.1.5 |
| Botulinum Type A | Botulinum Type A | Uncomplicated chronic anal fissure
| Formulary BNF 1.7
|
| Botulinum Type A | Botulinum Type A | Hyperhidrosis (excessive sweating) in people with social anxiety disorder. | Formulary BNF
NICE CG159 |
| Brentuximab vedotin | Adcetris® | Untreated advanced Hodgkin lymphoma NICE TA594 - appraisal terminated. | Formulary BNF 8.1 |
| Brimonidine | Mirvaso® | Facial erythema in rosacea | Formulary BNF 13.6
|
| Bromfenac | Yellox® | Postoperative inflammation following cataract surgery | Formulary BNF 11.8
|
| Budesonide oral capsules | Entocort® | 2nd line corticosteroid option in crohn's disease when conventional corticosteroid not tolerated | Formulary BNF 1.5
|
| Buspirone | Buspar® | Anxiety (short term use)
| Formulary BNF 4.3
|
| Cabazitaxel | Jevtana® | Prostate Cancer
| Formulary BNF 8.1
|
| Cabozantinib | Cometriq | NICE was unable to make a recommendation about the use of Cabazantinib for previously treated advanced hepatocellular carcinoma - appraisal terminated _ NICE TA582 | Formulary BNF 8'1 |
| Cannabis based Medicinal products | | Management of Chronic Pain - See Position Statement | Formulary BNF 4.7 |
Canabis extract
buccal spray | Sativex® | Spasticity in multiple sclerosis Existing patients to be referred for review NICE CG186 | Formulary BNF 10.2
|
| Canakinumab | Ilaris® | Gout NICE TAG281
| Formulary BNF 8.2.4
|
| Cangrelor | Kangrexal® | Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. Appraisal terminated NICE TA351
| Formulary BNF 2.9
|
| Capsaicin 179 mg (8%) Patches | Qutenza® | Peripheral neuropathic pain in non-diabetic patients | Formulary BNF 10.3
|
| Carmustine implant | Gliadel® | Recurrent glioblastoma multiforme NICE TA149
Appraisal terminated. | Formulary BNF 8.1
|
| Casodex® | Casodex® | Generic Prescribing Only
| Formulary BNF 8.3
|
| Cenegermin | Oxervate | Not recommended, within its marketing authorisation, for treating moderate to severe neurotrophic keratitis in adults - NICE TA532 | Formulary BNF 11 |
| Cetuximab | Erbitux® | Metastatic colorectal cancer 2nd line, (montherpay or combination chemo) NICE TA242 | Formulary BNF 8.1
|
| Cholestyramine 10% in cetomacrogol | | Refer patient back to original prescriber | Formulary BNF 13 |
Cilostazol
| Pletal® | Intermittent claudication NICE TA223 | Formulary BNF 2.6
|
| Clarithromycin Straws | Clarosip® | Discontinued
| Formulary BNF 5.1
|
| Clarithromycin XL | Klaricid XL® | Respiratory tract infections
| Formulary BNF 5.1
|
| Co-aprovel® | Co-aprovel® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Co-careldopa Intestinal Gel | Duodopa® | Severe Parkinson's disease | Formulary BNF 4.9
|
| Cobimetinib | Cotellic® | Unrescetable or metastatic BRAF V600 mutation positive melanoma, in combination with vemurafenib
NICE TA414 | Formulary BNF 8.1
|
Co-enzyme Q10/ Ubiquinone/ Ubidecarenone
| Co-enzyme Q10 | Except for mitochondrial disorders | Formulary BNF 9.8
|
| Colesevelam | Cholestagel® | Familial hypercholesterolaemia (combination or monotherapy) | Formulary BNF 2.12
|
| Co-phenotrope | all brands | Adjunct to rehydration in acute diarrhoea | Formulary BNF 1.4 |
| Co-proxamol | e.g. Cosalgesic®, Distalgesic®, Dolgesic®
| Unlicensed and only available on named patient basis | Formulary BNF 4.7
|
| Cozaar® | Cozaar® | Generic Prescribing Only
| Formulary BNF 2.5
|
| Crizotinib | Xalkori® | Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene - not recommended by NICE TAG296 | Formulary BNF 8.1
|
| Dapoxetine | Priligy® | Premature ejaculation in men 18-64 years of age.
| Formulary BNF 7.4
|
| Daratumumab | Daralex ® | Relapsed or refractory multiple myeloma (with dexamethasone and lenalinomide), Appraisal terminated. | Formulary BNF 8.1.5 |
| Daratumumab | Daralex ®
| Daratuzumab with lenalidomide and dexamethasone for untreated multiple myeloma - appraisal terminated. NICE was unable to make a recommendation as the company did not provide an evidence submission. | Formulary BNF 8.1.5 |
| Darvadstrocel | Alofisel | Darvadstrocel is not recommended, within its marketing authorisation, for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease. - NICE TA556 | Formulary BNF 1.5.2 |
| Decitabine | Dacogen® | Leukaemia, acute myeloid NICE TA270. Appraisal terminated | Formulary BNF 8.1
|
| Degludec with Liraglutide | Xultophy® | Type II diabetes mellitus.
| Formulary BNF 6.1
|
Denosumab
| Xgeva® | Bone loss in non-metastatic prostate cancer NICE TA194 Terminated appraisal. | Formulary BNF 6.6
|
| Dexamethasone intravitreal implant | Ozurdex® | Repeat treatment for posterior uveitis.
Position Statement
| Formulary BNF 11.4
|
| Dexibuprofen | Seractil® | Pain & inflammation | Formulary BNF 10.1
|
| Dibotermin alfa | InductOs® | Non-union long bone fractures [unlicensed indication] | |
| Diclofenac Gel Patch | Voltarol Gel Patch® | Pain & inflammation | Formulary BNF 10.3
|
| Diclofenac tablets | All brands | Non Steroidal Anti Inflammatory Drug | Formulary BNF 4.7
|
| Dicycloverine | Non-proprietary | Intestinal smooth muscle relaxant | Formulary BNF 1.2
|
| Diethylamine salicylate cream | Algesal® | Rubifacient | Formulary BNF |
| Diovan® | Diovan® | Generic Prescribing Only | Formulary BNF 2.5
|
| Dosulepin | Prothiaden® | Depressive illness | Formulary BNF 4.3
|
| Diclofenac & Misoprostol | Arthrotec® | Rheumatoid arthritis; osteoarthritis | Formulary BNF 10.1
|
| Disofrol® | Disofrol® | Intractable cough, unlicensed import from USA | Formulary BNF 3.0
|
| Dupilumab | Dupixent® | Chronic rhinosinusitis with nasal polyps NICE TA648 | Formulary BNF 13 |
| Durvalumab | Durvalumab | Untreated extensive-stage small-cell lung cancer [terminated appraisal] NICE TA662 | Formulary BNF 8.1. |
| E-Cigarettes | E-Cigarettes | Substitute to smoking tobacco
Position statement
| Formulary BNF 4.10
|
| Eculizumab | Soliris® | Refractory myasthenia gravis - NICE TA636 - terminated appraisal | Formulary BNF 8.1.5 |
| Eculizumab | Soliris® | Relapsing neuromyelitis optica - NICE TA647 appraisal terminated | Formulary BNF 8.1. |
| Efalizumab | Raptiva® | Licence currently suspended. | Formulary BNF 10.1
|
| Elfornithine | Vaniqa® | Facial hirsutism | |
| Elotuzumab | Empliciti | Previously treated multiple myeloma (terminated appraisal) NICE TA434 | Formulary BNF 8.2.3 |
| Eltrompobag | Revolade® | Severe aplastic anaemia refractory to immunosuppressive therapy - terminated appraisal. NICE TA382
| Formulary BNF 9.1
|
Entocort®
| Entocort® | Prescribe as Budenofalk® | Formulary BNF 1.5
|
| Enzalutamide | Xtandi | Hormone-relapsed non-metastatic prostate cancer - not recommended by NICE TA580 | Formulary BNF |
| Erdosteine | Erdotin® | Acute exacerbations of chronic bronchitis | Formulary BNF 3.7
|
| Eribulin | Halaven® | Locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy - not recommended as an option in NICE TA515 | Formulary BNF 8.1 |
| Erlotinib | Tarceva® | Monotherapy for maintenance treatment of non-small-cell lung cancer. NICE TA227 | Formulary BNF 8.1
|
| Escitalopram | Cipralex® | BLACK for Depression. GREEN for Generalised Anxiety Disorder | Formulary BNF 4.3
|
| Estriol 0.1% vaginal cream | Gynest® (Ortho) | Topical HRT | Formulary BNF 7.2 |
| Everolimus | Certican® | Preventing organ rejection in liver transplant. NICE TAG348
| Formulary BNF 8.1
|
| Everolimus | Certican® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Evolocumab | Repatha® | Prevention of cardiac events on patients with CHD and a history of ACS , in combination with a statin | Formulary 2.12 |
| Ezetimibe & Simvastatin | Inegy® | Primary (heterozygous-familial & non-familial) cholesterolaemia Prescribe separately, NICE TA132 | Formulary BNF 2.12
|
| Fampridine | Fampyra® | NHS England commissioned drug | Link to document
|
| Fentanyl Lozenge | Actiq® | Severe chronic pain | Formulary BNF 4.7
|
| Fentanyl nasal spray | Instanyl®, PecFent® | Severe chronic pain | Formulary BNF 4.7
|
| Fentanyl sublingual | Abstral®, Effentora® | Severe chronic pain | Formulary BNF 4.7
|
| Ferric Maltol | Feracrru® | Iron Deficiency Anaemia in patients with inflammatory bowel disease | Formulary BNF 9.1 |
| Fluconazole capsules & suspension | Diflucan® | Breast ductal thrush | Formulary BNF 5.2
|
| Fludarabine, oral | Fludara® | Leukaemia, lymphocytic, 1st line monotherapy NICE TA119 | Formulary BNF 8.1
|
| Fluocinolone Acetonide intravitreal implant | Iluvien® | Diabetic Macular Oedema NICE TA271 - replaced by NICE TA301 - RED Traffic Light | Formulary BNF 11.4
|
| Fluocinolone Acetonide intravitreal implant | Iluvien® | Chronic diabetic macular oedema that has inadequately responded to previous therapy, in adults whose eyes have natural lenses (phakic eyes). NICE TA613 | Formulary BNF 11.4
|
| Fluorouracil 0.5% + salicylic acid 10% | Actikerall® | Actinic keratosis | Formulary BNF 13.8
|
| Fluticasone & Formoterol inhaler | Flutiform® | Asthma | Formulary BNF 3.2
|
| Fluticasone furoate/Vilanterol | Relvar® Ellipta® | COPD in adults
Link to review
| Formulary BNF 3.1
|
| Fluticasone furoate | Avamys® | Nasal allergies | Formulary BNF 12.2
|
| Forceval® | Forceval® | BLACK for all indications except: Malabsorption = RED, | Formulary BNF 9.6
|
| Fulvestrant | Faslodex® | Breast cancer, locally advanced or metastatic. NICE TA239 | Formulary BNF 8.3
|
Fulvestrant
| Faslodex®
| Locally advanced or metastatic oestrogen-receptor positive breast cancer in post menopausal women who have not had endocrine therapy before | Formulary BNF 8.3 |
| Gabapentin Liquid | Non-proprietary | Seizures, neuropathic pain | Formulary BNF 4.8 |
| Gamolenic Acid | Efamast® Epogam® Evening Primrose Oil® | Dietary supplement | |
| Gefitinib | Iressa® | Lung cancer, NSC, 2nd line. NICE TA175
| Formulary BNF 8.1
|
| Gefitinib | Iressa® | Non-small-cell lung cancer that has progressed after prior chemotherapy. NICE TA374 | Formulary BNF 8.1
|
| Gemcitabine infusion | Non-proprietary | In combination with carboplatin for treating the first recurrence of platinum‑sensitive ovarian cancer, as perNICE TA389 | Formulary BNF 8.1
|
| Gentamicin & Hydrocortisone | Gentisone HC® | Eczematous inflammation in otitis externa | Formulary BNF 12.1 |
| Glasdegib with chemotherapy | | Untreated acute myeloid leukaemia NICE TA646 - appraisal terminated | Formulary BNF 8.1 |
| Glucosamine | Alateris®
Glusartel® | Osteoarthritis of the knee - NICE Do Not Do Recommendation | Formulary BNF 10.1
|
| Gluten Free Food Products | Gluten Free Food Products | Coeliac disease or other gluten intolerances. | Link to Commissioning Statement |
| Golimumab | Simponi® | BLACK for Methotrexate naive patients with Rheumatoid Arthritis. NICE TA224 RED as an option for Rheumatoid Arthritis NICE TA225, Psoriatic Arthritis NICE TA220 and Ankylosing Spondylitis NICE TA233 | Formulary BNF 10.1
|
| Golimumab | Simponi® | Moderate to severe active ulcerative colitis. Position Statement | Formulary BNF 1.5
|
| Grass pollen extract | Grazax®
| Grass & tree pollen allergy. New Drug Review
| Formulary BNF 3.4
|
| Haemophilus type b and Meningococcal group C conjugate vaccine | Menitorix | Adminstration in patients with rsepiratory conditions. Not recommended for prescribing on the NHS in Lancashire and South Cumbria. See supporting Document
| |
| Heliox® | Heliox® | Not commissioned for vocal chord dysfunction | |
| Hepatitis B Vaccine | | Travel vaccination | See Position Statement |
Hyaluronic Acid
| Durolane®, Euflexxa®, Fermathron®, Hyalgan®,
Orthovisc®, Ostenil®,
Ostenil Plus®, RenehaVis®
Suplasyn®, Synocrom®,
Synopsis®, Synvisc®, SportVis®
| Osteoarthritis (all joints) NICE CG177 (update of CG59) | Formulary BNF 10.1
|
| Hydrocortisone MR | Plenadren®
| Treatment of adrenal insufficiency
| Formulary BNF 6.3
|
Hydrogen peroxide 1% cream
| Crystacide®
| Skin infection, infected eczema
| Formulary BNF 13.11
|
Ibrutinib with bendamustine and rituximab
| | Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) NICE TA437 | Formulary BNF 8.1.5 |
| Ibrutinib | Imbruvica ▼
| Untreated chronic lymphocytic leukaemia without a 17p deletion or Tp53 mutation (terminated appraisal) | Formulary BNF 8.1.5 |
| Ibrutinib | Imbruvica ▼ | (with rituximab) for treating Waldenstrom's macroglobulinaemia - NICE TA608 - appraisal terminated | Formulary BNF 8.1.5 |
Icatibant
| Firazyr®
| Hereditary angioedema in patients with C1-esterase inhibitor deficiency.
| Formulary BNF 3.4
|
Idelalisib
| Zydelic® ▼
| Follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
NICE TA328
| Formulary BNF 8.1
|
| Idelalisib | Zydelic® ▼
| Chronic lymphocytic leukamia | Formulary BNF 8.1.5 |
| Idelalisib | Zydelic® ▼ | Not recommended,within its marketing authorisation, for traeting Follicular lymphoma that has not responded to 2 prior lines of treatment in adults. NICE TA604 | Formulary BNF 8.1 |
Idrolax®
| Idrolax®
| Osmotic laxative
| Formulary BNF 1.6
|
Imatanib, high dose
| Glivec®
| GIST, unresectable/ metastatic NICE TA209
| Formulary BNF 8.1
|
| Imipramine | Non-proprietary | Neuropathic Pain | FormularyBNF 4.7 |
Imiquimod 3.75%
| Zyclara®
| Actinic keratosis
| Formulary BNF 13.8
|
Influenza Vaccine (Intadermal)
| Intanza®
| 9 or 15 microgram / strain
| MMB Decision - INTERFACE
|
| Inositol Nicotinate | Hexopal® | Peripheral vascular disease. NICE TA223 | Formulary BNF 2.6 |
| Insulin glargine/lixisenatide | Suliqua®▼ | In combination with metformin for the treatment of adults with T2DM to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin | Formulary BNF 6.1 |
| Intrabeam radiotherapy system | | Adjuvant treatment of early breast cancer NICE TA501 | |
| Japanese Encephalitis Vaccine | | Travel vaccination | See Position Statement |
| Ketamine (oral) | unlicensed | Chronic pain - limited clinical evidence. | Formulary BNF 4.7
|
| Ketamine infusion | | Non - fromulary | Formulary BNF 4.7 |
| Ketotifen eye drops 0.25mg/ml | Ketofall ® | Symptomatic treatment of seasonal allergic conjunctivitis | Formulary BNF 11.4 |
Lapatinib
| Tyverb®
| In combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive. NICE TA257
| Formulary BNF 8.1
|
| Lenalidomide | Revlimid® | Untreated multiple myeloma - appraisal terminated - NICE TA603 | Formulary BNF 8.2.4 |
| Lesinurad | Ziurampic® | Chronic hyperuricaemia in adults with gout - not recommended by NICE TA506 | Formulary BNF |
Levocetirizine
| Xyzal®
| Antihistamine
| Formulary BNF 3.4
|
| Levomepromazine tablets 6mg | Non -proprietary | Pain, nausea, agitation in palliative care. | Formulary BNF 4.6 |
| Levothyroxine Liquid | | Hypothyroidism | Formulary BNF 6.2 |
| Lidocaine/Prilocaine Spray | Fortacin®
| Primary premature ejaculation in adult men | Formulary BNF 7.4.5 |
Liothyronine 20mcg tablets
| | Add on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxine
| Formulary BNF 6.2
|
| Liothyronine 20mcg tablets | | Monotherapy for the chronic management of hypothyroidism - not licensed. Not for use by the NHS in Lancashire | |
| Liothyronine 20mcg tablets | | Management of resistant depression - not licensed, Not for use by the NHS in Lancashire | |
| Lipitor® | Lipitor® | Generic prescribing only | Formulary BNF 2.12
|
| Liraglutide | Saxenda▼
| Adjunct to reduced-calorie diet and increased physical activity for weight management in adult patients
| Formulary BNF 6.1 |
| Loprazolam | Non-proprietary
| Hypnotic | Formulary BNF 4.1
|
Lormetazepam
| Non-proprietary
| Hypnotic | Formulary BNF 4.1
|
Losartan and Hydrochlorothiazide
| Cozaar Comp®
| Hypertension
| Formulary BNF 2.5
|
|
|
| |
Losec®
| Losec®
| Generic Prescribing Only
| Formulary BNF 1.3
|
Loxapine
|
| Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder NICE TA286
| Formulary BNF 4.2
|
Lumacaftor-ivacaftor
| Orkambi
| Cystic Fibrosis in people 12 years and older who are homozygous for the F508del mutation
NICE TAG398
| Formulary BNF 3.7
|
Lumiracoxib
| Prexige®
| Discontinued | Formulary BNF 10.1
|
Lutein
| ICAPS®, Vitalux Plus® | Dietary supplement
| ICAPS - New Drug Review
|
Melatonin
| Circadin®
| Primary insomnia in adults
| Formulary BNF 4.1
|
| Meningitis Vaccine | | Travel vaccination | See Position Statement |
Methylnaltrexone
| Relistor® | Opioid-induced bowel dysfunction in people with advanced illness receiving palliative care NICE TAG277 & NICE TA468
| Formulary BNF 1.6
|
| Minocycline tablet | | Non-formulary - in line with NHSE low priority prescribing commissioning guidance | Formulary BNF 5.1 |
Minocycline MR
| Acnamino®MR, Minocin MR®, Sebomin MR®
| Acne
| FormularyBNF 5.1
|
Mirapexin®
| Mirapexin®
| Generic Prescribing Only
| Formulary BNF 4.9
|
Modulen IBD®
| Modulen IBD®
| Food supplement
| Formulary BNF
|
Mugard®
| Mugard®
| Mucositis from cancer therapy
| Formulary BNF 12.3
|
| Mycophenolate Sodium | Myfortic®, Ceptava®
| Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
| Naproxen & Esomeprazole | Vimovo®
| Pain & inflammation
| Formulary BNF 10.1
|
| Naltrexone-bupropion | Mysimba® | Management of overweight and obesity in adults | Formulary |
Naltrexone
| Nalorex® Opizone® | Treatment of advanced ovarian cancer
| Formulary
|
Nebulised Amoxycillin
|
| Not licensed for use via nebulised route for bronchiectasis or any other indication
| Formulary
|
Necitumumab
| Portrazza
| Untreated advanced or metastatic squamous non-small-cell lung cancer. NICE TA411
| Formulary BNF 8.2
|
| Nefopan | all brands | Non opioid analgesia | Formulary BNF 4.7 |
Nicotine Strips
| NiQuitin Strips®
| Nicotine Replacement Therapy
| Formulary BNF 4.10
|
| Nivolumab | Opdivo® | Not recommended within its marketing authorisation , for treating locally advanced unresectable or metastatic urothelial carcinoma in adults - as per NICE TA530 | Formulary BNF 8.1.5 |
Norfloxacin
| Utinor®
| Prophylaxis of spontaneous bacterial peritonitis
| Formualry BNF 5.1
|
| Nortriptyline | Non-proprietary | Depressive illness | Formulary BNF 4.3 |
Ofatumumab
| Arzerra®
| Chronic lymphocytic leukaemia, NICE TA202 | Formulary BNF 8.2
|
| Ofatumumab | Arzerra® | Chronic lymphocytic leukaemia (with chemotherapy) | Formulary BNF8.2.3 |
| Olanzapine Embonate Depot Injection | ZypAdhera®
| Schizophrenia
| Formulary BNF 4.2
|
Omalizumab
| Xolair®
| BLACK for children under 6 . RED for adults and children over 6. NICE TA278 | Formulary BNF 3.3
|
| Omalizumab |
Xolair® |
Chronic rhinosinusitis with nasal polyps.
Not recommended for prescribing on the NHS in Lancashire. NICE TA678 (Appraisal terminated)
|
Formulary BNF 3.4. |
Omega-3 acid ethyl esters
| Omacor® | Hyper-triglyceridaemia. NHS England has identified this product as an item that should not be routinely prescribed in primary care. It is available to purchase over the counter | Formulary BNF 2.12 |
| Omeprazole liquid | Non-proprietary | Gastro-oesophageal reflux | Formulary BNF 1.3.5 |
| Ospemifene | Senshio® | Moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy | Formulary BNF 7.2.1 |
Oxycodone hydrochloride/ naloxone hydrochloride
| Targinact®
| Restless Legs Syndrome
| Formulary BNF 4.9
RLS Guidelines
|
Oxycodone hydrochloride/ naloxone hydrochloride
| Targinact®
| Severe pain
| Formulary BNF 4.7
|
Omega-3 acid ethyl esters
| Omacor®
| Post Myocardial Infarction. NHS England has identified this product as an item that should not be routinely prescribed in primary care. It is available to purchase over the counter
| Formulary BNF 2.12
|
Paclitaxel
| Abraxane®, Taxol® | Breast cancer, early (NICE TA108)
| Formulary BNF 8.1
|
Paclitaxel
| Abraxane®
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE TA362
| Formulary BNF 8.1
|
| Padeliporfin | Tookad® | Padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults - NICE TA546 | Formulary BNF |
Paliperidone tablets
| Invega®
| Schizophrenia
| Formulary BNF 4.2
|
Panitumumab (in combination with chemotherpay)
| Vectibix®
| Metastatic colon cancer (appraisal terminated) NICE TA240 updated March 17
| Formulary BNF 8.1
|
Panitumumab
| Vectibix®
| Monotherpay of metastatic colorectal cancer 2nd line (NICE TA242)
| Formulary BNF 8.1.5
|
Pantoprazole
| Protium®
| Proton pump inhibitor
| Formulary BNF 1.3
|
Paricalcitol
| Zemplar®
| Secondary hypoparathyroidism
| Formulary BNF 9.6
|
Pegaptanib
| Macugen®
| Age-related macular degeneration, (NICE TA155) | Formulary BNF 11.8
|
Pegloticase
| Krystexxa®
| Gout (NICE TA291)
| Formulary BNF 10.
|
| Pegylated liposomal irinotecan | Onivyde | Pancreatic cancer in adults after gencitabine (NICE TA440) | Formulary BNF 8.1 |
| Pembrolizumab | Keytruda® | Not recommended as an option to treat relapsed or erfarctory classical Hodgkin lymphoma in adults who have had auologous atem cell transplant and brentuximab vedotin as per NICE TA540 | Formulary BNF 8.1 |
| Pembrolizumab | Keytruda® | Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (NICE TA570) - appraisal terminated.
NOT recommended for prescribing on the NHS in Lancashire
| Formulary BNF 8.1.5 |
| Pembrolizumab | Keytruda® | Not recommended, with axitinib, for untreated advanced renal cell carcinoma NICE TA650 | Formulary BNF 8.1.5 |
| Pembrolizumab | Keytruda® | Not recommended for prescribing on the NHS in Lancashire NICE TA674 [appraisal terminated] | Formulary BNF 8.1 |
Pentoxifylline
| Trental®
| Peripheral vascular disease, (NICE TA223) | Formulary BNF 2.6
|
Perindopril Arginine
| Coversyl®
| Use generic perindopril erbumine
| Formulary BNF 2.5
|
Pioglitazone15mg/ Metformin 850mg
| Competact®
| Type 2 diabetes mellitus
| Formulary BNF 6.1
|
| Pitolisant | Wakix® | Narcolepsy with or without cataplexy in adults | Formulary BNF 4.4 |
Plavix®
| Plavix® | Generic prescribing only - Plavix may be supplied against a generically written prescription.
| Formulary BNF 2.9
|
| Pomalidomide | Imnovid® | Relapsed or refractory multiple myeloma (with bortezomib and dexamethasone) - NICE TA602 - appraisal terminated | Formulary BNF 8.2.4 |
| Potassium hydroxide 5% | Molludab ® | Molluscum | Formulary BNF |
| Prasterone | Intrarosa® | Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms | Formulary BNF 7.2 |
Praxilene®
| Praxilene®
| Generic prescribing only
| Formulary BNF 2.6
|
| Prednisolone Soluble | All brands
| Suppression of inflammation and allergic disorders
| Formulary BNF 6.3
|
Prednisolone 5mg EC
| Deltacortril®
| Use non-EC tabs, where possible, 2.5mg EC tabs remain GREEN
| Formulary BNF 6.3
|
Prednisone
| Lodatra®
| Moderate to severe rheumatoid arthritis
| Formulary BNF 6.3
|
Pregabalin
| Lyrica®
| Generalised Anxiety disorder Joint Formulary for Psychotropic Medication LCFT
| Formulary BNF 4.3
|
Pregabalin
| Lyrica®
| Epilepsy only
| Formulary BNF 4.8
|
| Pregabalin Liquid | all brands | Epilepsy, GAD, neuropathic pain | Formulary BNF 4.7 |
Progesterone Cream
|
| Unlicensed
| Formulary BNF 6.4
|
Rabeprazole
| Pariet®
| Proton pump inhibitor
| Formulary BNF 1.3
|
| Rabies vaccine | | Travel vaccination | See Position Statement |
Ramucirumab
| Cyramza®
| Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
NICE TAG 378
| Formulary BNF 8.3 |
Ramucirumab
| Cyramza®
| locally advanced or metastatic non-small-cell lung cancer , in combination with docetaxel, in adults whose disease has progressed after platinum-based chemotherapy. NICE TA403
| Formulary BNF 8.1
|
Ramucirumab
| Cyramza®
| With erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer NICE TA635 - terminated appraisal | Formulary BNF 8.1.5 |
| Ramucirumab | Cyramza® | Unresectable hepatocellular carcinoma in adults who have had sorafenib - NICE TA609 - terminated appraisal | Formulary BNF 8.1 |
| Ranibizumab | Lucentis® | Diabetic retinopathy - NICE TA637 - terminated appraisal | Formulary BNF 11.8.2 |
| Recombinant human parathyroid hormone | | Hypoparathyroidism - appraisal terminated | Formulary 6.6 |
Regorafenib
| Stivarga®
| Metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) NICE TA334
| Formulary BNF 8.1
|
| Regorafenib | Stivarga® | Previously treated advanced hepatocellular carcinoma in adults - not recommended as an option in NICE TA514 | Formulary BNF 8.1 |
RESPeRATE ®
| RESPeRATE®
| Black for Adjunct treatment of Hypertension
| Formulary BNF 2.5
|
Retapamulin
| Altargo®
| Superficial bacterial infections
| Formulary BNF 13.10
|
Risedronate
| Actonel®
| Osteoporosis, primary prevention (NICE TA160)
| Formulary BNF 6.6
|
Rituximab
| MabThera®
| Pemphigus
| Formulary BNF 8,2
|
Rituximab
| MabThera®
| Multi drug resistant, steroid dependent, frequently relapsing nephrotic syndrome
| Formulary BNF 8.2
|
Rituximab
| MabThera®
| Resistant coeliac disease
| Formulary BNF 8.2
|
| Safinamide | Xadago®
| Idiopathic Parkinson's disease
New Medicines Recommendation | Formulary BNF 4.9
|
Salbutamol SR tablets
| Ventmax SR®
| Asthma
| Formulary BNF 3.1
|
Salmeterol MDI
| Neovent®
| Asthma
| Formulary BNF 3.1
|
Sea Water nasal drops
| Sterimar®
| Nasal decongestant
| Formulary BNF 12.2
|
Selenium
| Oral food supplement
| Post bariatric surgery - patient to purchase own. link to Guidelines
| Formulary BNF 9.5
|
Sertindole
| Serdolect®
| Schizophrenia
| Formulary BNF 4.2
|
Silicone Gel Sheets
| Scarsil®, Silgel STC-SE®, Dermatix®, Ciltech®, NewGel®, Kelocote®, Advasil Conform ®, Cica-Care®
| Hypertrophic and keloid scarring
| Formulary woundcare
|
Silk Garments
| Dermasilk®, Dreamskin®, Skinnies Silk TM | Eczema/atopic dermatitis
| ELHE Position statement
|
Simeprevir
| Olysio®
| Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal). NICE TA361
| Formulary BNF 5.3
|
Simvastatin Suspension
| Rosemont brand
| Primary hypercholesterlaemia
| Formulary BNF 2.12
|
Sipuleucel-T
|
| Asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer as by NICE TA332
| Formulary BNF 8.3
|
| Sirolimus | Rapamune® | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
Sitagliptin & Metformin
| Janumet®
| Type II Diabetes, (prescribe drugs separately) | Formulary BNF 6.1
|
| Sodium Chloride nebules 0.9% | | For dilution of solutions for nebulisation. | Formulary BNF 3.7 |
Sodium Chondroitin sulphate 2% bladder washout
| Uracyst®
| Painful bladder syndrome
| Formulary BNF 7.4
|
Sodium Hyaluronate Injection
| Durolane® Hyalgan® Ostenil®
| BLACK for OA of the knee. RED for all other indications | Formulary BNF 10.1
|
Sodium Oxybate
| Xyrem®
| Narcolepsy with cataplexy New Medicine Recommendation
| Formulary BNF 4.1
|
Solifenacin 6mg/ tamsulosin 400mcg MR
| Vesomni®
| Symptoms associated with benign prostatic hyperplasia
| Formulary BNF 7.4
|
Sorafenib
| Nexavar®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
| St Johns Wort (Hypericum) | | Depression
| Formulary BNF 4.3
|
Sunitinib
| Sutent®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
| Tacrolimus Prolonged Release | Advagraf®, Envarsus | Immunosuppressive therapy for kidney transplant in adults NICE TA481 (adults) NICE TA482 (Children and young adults) | Formulary BNF 8.2 |
Tadalafil
| Cialis®
| Benign prostatic hyperplasia
(NICE TA273)
| Formulary BNF 7.4
|
Tadalafil once daily
| Cialis®
| Post prostatectomy
| Formulary BNF 7.4
|
Tadalafil 2.5, 5mg
| Cialis®
| Erectile Dysfunction
| Formulary BNF 7.4
|
Tamsulosin MR Tablets
| Flomaxtra XL®
| Benign prostatic hyperplasia
| Formulary BNF 7.4
|
Tapentadol MR
| Palexia SR®
| Not recommended for use as a treatment option for intractable neuropathic pain in non-palliative care patients. Link to Position Statement
| Formulary BNF 4.7.2
|
Tapentadol MR
| Palexia SR®
| Not recommended for use as a treatment for non-specific pain. Link to Position Statement
| Formulary BNF 4.7
|
Taurine
| Taurine
| Supplementation in Cystic Fibrosis Liver Disease
|
|
Telbivudine
| Sebivo®
| Chronic Hepatits B
| Formulary BNF 5.3
|
Temsirolimus
| Torisel®
| Renal cell carcinoma (NICE TA178)
| Formulary BNF 8.1
|
Temsirolimus
| Torisel®
| Mantle Cell Lymphoma, (NICE TA207) | Formulary BNF 8.1
|
| Tenofovir alafenamide | | Chronic hepatitis B (terminated appraisal) NICE TA 435 | Formulary BNF 8.2.3 |
Teriparatide
| Forsteo®
| BLACK for treatment of osteoporosis in MEN at increased risk of fractures, RED for for prevention of osteoporotic fragility fractures in postmenopausal women.(NICE TA160/161) | Formulary BNF 6.6
|
Testosterone gel
| Testim®
| Female sexual dysfunction post oophorectomy or primary ovarian failure
| LMMG new medicine assessment
|
| Testosterone patches Testosterone mucoadhesive buccal tablets. Testosterone gel | Intrinsa®
Striant SR®
Testogel®
| Hypoactive sexual desire in surgically induced menopause. Link to New Drug Review
| Formulary BNF 6.4
|
| Testosterone mucoadhesive buccal tablets | Striant SR®
| Hypogonadism
| Formulary BNF 6.4
|
| Testosterone Patches Testosterone mucoadhesive buccal tablets Testosterone gel | Intrinsa®
Striant SR®
Testogel®
| Male low libido
| Formulary 6.4 |
| Tick Borne Encephalitis vaccine | | Travel vaccination | See Position Statement |
Tolvaptan
| Samsca®
| Hyponatraemia
| Formulary BNF 6.5
|
Topotecan, IV
| Non-proprietary
| Lung cancer, small cell (NICE TA184)
| Formulary BNF 8.1
|
Topotecan, IV
| Non-proprietary
| Not recommended within its marketing authorisation for treating the first recurrence of platinum‑sensitive ovarian cancer. NICE TA389
| Formulary BNF 8.1
|
Topotecan, IV
| Non-proprietary
| Recurrent platinum‑resistant or platinum‑refractory ovarian cancer (not recommended) in NICE TA389
| Formulary BNF 8.1
|
Trabectedin
| Yondelis®
| Relapsed platinum sensitive ovarian cancer when in combination with PLDH. (NICE TA222) | Formulary BNF 8.1
|
Trabectedin
| Yondelis®
| Trabectedin in combination with PLDH is not recommended within its marketing authorisation for treating the first recurrence of platinum‑sensitive ovarian cancer. NICE TA389
| Formulary BNF 8.1
|
Tramadol and Paracetamol
| Tramacet®
| Moderate to severe pain
| Formulary BNF 4.7
|
Trastuzumab
| Herceptin®
| In combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive (NICE TA257)
| Formulary BNF 8.1
|
Triamcinolone Hexadetonide Injection
|
| Approved for use for JIA only in ELHE - Not approved for other indications
| Formulary BNF 10.1
|
| Trifluridine-tipiracil | Lonsurf | Metastatic gstric cancer or gastro-oesophageal junction adenocarcinoma NICE TA669 | Fomulary BNF 8.1 |
| Trimipramine | | Depressive illness/neuropathic pain | Formulary BNF 4.3 |
| Ulipristal | Esmya® | Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. See MHRA Alert February 2018 | Formulary 6.4 |
Umeclidinium
| Incruse®▼
| COPD | Formulary BNF 3.1
|
Valsartan and Amlodipine
| Exforge®
| Hypertension
| Formulary BNF 2.6
|
| Vandetanib | Caprelsa | Vandetanib is not recommended, within its marketing authroisation , for treating aggressive and symtomatic medullary thyroid canmer in adults as in NICE TA550 | Formulary BNF 8. |
Vardenafil
| Levitra®
| Those patients prescribed this before July 2012 may continue on it
| Formulary BNF 7.4
|
| Vernakalant | Brinavess | Rapid conversion of recent onset atrial fibrilation to sinus rhythm in adults . Not recommend for prescribing on the NHS in Lancashire. NICE TA675 [appraisal terminated] |
Formulary BNF 2.3.2 |
Viagra®
| Viagra®
| Generic Prescribing Only
| Formulary BNF 7.4
|
Vinflunine
| Javlor®
| Urothelial tract carcinoma
| Formulary BNF 8.1
|
Vildagliptin
| Galvus®
| Type II Diabetes / Use sitagliptin | Formulary BNF 6.1
|
| Vismodegib | Erivedge | Basal cell carcinoma | Formulary BNF 8.1 |
Vitamin D capsules
| Fultium®
| Vitamin D deficiency
| Formulary BNF 9.6
|
| Vitamins, minerals, supplements, herbal and homeopathic medicines without a product licence | | Link to position statement | Formulary BNF 9 |
| Yellow fever Vaccine | | Travel vaccination | See Position Statement |
Zinc
| Oral food supplement
| Post bariatric surgery - patient to purchase own
| |
| | | | |
| | | | |
| | | | |
